2022
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Annals Of Hematology 2022, 101: 557-569. PMID: 34981142, PMCID: PMC9414073, DOI: 10.1007/s00277-021-04734-2.Peer-Reviewed Original ResearchConceptsAnti-drug antibodiesAcute myeloid leukemiaDose-limiting toxicityRefractory acute myeloid leukemiaHigh-risk myelodysplastic syndromeMyelodysplastic syndromeMyeloid leukemiaCommon treatment-emergent adverse eventsTreatment-emergent adverse eventsADA-positive patientsPhase 2 dosePresence/frequencyUnexpected safety findingsPhase 1 studyAnti-CD47 antibodyCD47-SIRPα interactionMacrophage-mediated killingHematological cancer cell linesFebrile neutropeniaMonotherapy activityCancer cell linesPrimary endpointSecondary endpointsAdverse eventsObjective response
2017
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczesny S, Konig H. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. International Journal Of Molecular Sciences 2017, 18: 1660. PMID: 28758974, PMCID: PMC5578050, DOI: 10.3390/ijms18081660.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsAntineoplastic Agents, ImmunologicalHumansImmunotherapyLeukemia, Myeloid, AcuteTumor MicroenvironmentConceptsLeukemic microenvironmentAllogeneic stem cell transplantationLong-term disease controlAcute myeloid leukemia (AML) treatmentMonoclonal antibodiesIntensive chemotherapeutic protocolsImmune-based therapiesMajority of patientsOverall survival rateStem cell transplantationManagement of AMLAcute myeloid leukemiaElicit immune responsesMyeloid leukemia treatmentEarly phase studiesNovel treatment conceptsImmunotherapeutic interventionsMost patientsAML therapyImmunotherapeutic conceptsPoor outcomeCell transplantationToxic therapiesChemotherapeutic protocolsMyeloid leukemia